149
Views
0
CrossRef citations to date
0
Altmetric
Case reports

Cerebellar Hemangioblastoma with Leptomeningeal Spread and a Fatal Outcome: A Rare Case Report with MDM2 and EGFR Alterations

ORCID Icon, , ORCID Icon, , , , ORCID Icon, , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 709-714 | Received 23 Jul 2023, Accepted 21 Oct 2023, Published online: 03 Nov 2023

References

  • Hussein MR. Central nervous system capillary haemangioblastoma: the pathologist’s viewpoint. Int J Exp Pathol. 2007;88(5):311–324. doi:10.1111/j.1365-2613.2007.00535.x
  • Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82–94. doi:10.3171/jns.2003.98.1.0082
  • Tihan T, Fanburg-Smith JC, Oliver Vortmeyer A, Zagzag D. Haemangioblastoma. In: Central Nervous Tumours Who Classification of Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2021.
  • Shankar GM, Taylor-Weiner A, Lelic N, et al. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. acta neuropathol commun. 2014;2(1):167. doi:10.1186/s40478-014-0167-x
  • Nguyen HS, Doan NB, Gelsomino M, et al. Intracranial hemangioblastoma - A SEER-based analysis 2004–2013. Oncotarget. 2018;9(46):28009–28015. doi:10.18632/oncotarget.25534
  • Muscarella LA, la Torre A, Faienza A, et al. Molecular dissection of the VHL gene in solitary capillary hemangioblastoma of the central nervous system. J Neuropathol Exp Neurol. 2014;73(1):50–58. doi:10.1097/NEN.0000000000000024
  • Minervini G, Quaglia F, Tabaro F, Tosatto SCE, Schlessinger A. Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors. PLoS Comput Biol. 2019;15(4):e1006478. doi:10.1371/journal.pcbi.1006478
  • North PE, Mizeracki A, Mihm MC, Mrak RE. GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma. Clin Neuropathol. 2000;19(3):131–137.
  • Liu Z, Li L, Yi Z, et al. Overexpression of EGFR and TGFα in von Hippel-Lindau related central nervous system hemangioblastomas. Front Oncol. 2020;10:703. doi:10.3389/fonc.2020.00703
  • Böhling T, Hatva E, Kujala M, Claesson-Welsh L, Alitalo K, Haltia M. Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol. 1996;55(5):522–527. doi:10.1097/00005072-199605000-00004
  • Mehrian-Shai R, Yalon M, Moshe I, et al. Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis. BMC Genomics. 2016;17(1):56. doi:10.1186/s12864-016-2370-6
  • Reifenberger G, Reifenberger J, Bilzer T, Wechsler W, Collins VP Coexpression of transforming growth factor-alpha and épidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. Am J Pathol. 1995;147(2):245-250.
  • Chen GJ, Karajannis MA, Newcomb EW, Zagzag D Overexpression and activation of epidermal growth factor receptor in hemangioblastomas. J Neurooncol. 2010;99(2):195-200. doi:10.1007/s11060-010-0125-9
  • Falconieri A, Minervini G, Bortolotto R, et al. The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel-Lindau tumor suppressor. Sci Rep. 2020;10(1):15850. doi:10.1038/s41598-020-72683-3
  • Ordookhanian C, Kaloostian PE, Ghostine SS, Spiess PE, Etame AB. Management strategies and outcomes for VHL-related craniospinal hemangioblastomas. J Kidney Cancer VHL. 2017;4(3):37–44. doi:10.15586/jkcvhl.2017.90
  • Huang Y, Chan L, Bai HX, et al. Assessment of care pattern and outcome in hemangioblastoma. Sci Rep. 2018;8(1):11144. doi:10.1038/s41598-018-29047-9